Pharmaceutical companies possess vast amounts of data, yet often there are challenges to leverage it effectively in their advertising campaigns for drugs. Campaign decisions by advertising companies are primarily made based on prior experiences and intuition rather than data-driven insights. The challenge lies in harnessing data about doctors’ historical engagement, demographics, and affinity to create more targeted and effective campaigns.
The SmartCat team tackled this challenge by developing the NBE (Next Best Experience) model, which provides data-driven insights into activating doctors through best possible channels. This approach allows clients to prioritize channels that are most likely to engage doctors, thereby boosting conversion rates. By ranking each channel based on the probability of positive engagement, SmartCat enabled clients to make informed decisions about resource allocation. Collaborating closely with clients, SmartCat identified and utilized a unique combination of features during model training and inference, optimizing the efficacy of the solution.
The implementation of the NBE model led to significant improvements in campaign performance. Moreover, a majority of doctors from target lists for multiple campaigns were successfully assigned to suitable channels, demonstrating the effectiveness of the data-driven approach.
The NBE model leveraged the XGBoost algorithm as its foundation. Development and deployment were facilitated using AWS SageMaker, with features and pipelines stored in the Feature Store. Results were stored in Snowflake, with metadata and pipelines stored on AWS cloud infrastructure.
A leading global provider of life sciences services, employing over 6000 professionals across multiple sectors, including pharmaceutical advertising, partnered with SmartCat to develop the AI component of their omnichannel solution, aiming to enhance the effectiveness of pharmaceutical advertising campaigns.